MAI Capital Management
CMPX icon

MAI Capital Management’s Compass Therapeutics CMPX Stock Holding History

MAI Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-14,189
Closed -$31.1K – 2097
2026
Q2 		$31.1K Buy
14,189
+13,575
+2,211% +$40.1K ﹤0.01% 2024
2026
Q1 		$3.25K Buy
614
+590
+2,458% +$3.4K ﹤0.01% 3721
2025
Q4 		$129 Buy
+24
New +$111 ﹤0.01% 4123

Other funds holding CMPX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

MAI Capital Management's CMPX Position: Q3 2026 in Review

MAI Capital Management sold out of Compass Therapeutics (CMPX) in Q3 2026, closing a stake of 14,189 shares — an estimated $31.1K sold.

MAI Capital Management first reported a position in CMPX in Q4 2025 and held it in 3 quarters. The position peaked at $31.1K in Q2 2026. 116 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • MAI Capital Management reported no remaining Compass Therapeutics position as of Q3 2026 after selling out during the quarter.
  • MAI Capital Management sold 14,189 Compass Therapeutics shares in Q3 2026, an estimated $31.1K.
  • MAI Capital Management first reported a position in Compass Therapeutics in Q4 2025 and held it in 3 quarters.
  • MAI Capital Management's Compass Therapeutics position peaked at $31.1K in Q2 2026.
  • 116 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on MAI Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.